Ramsay (ASX:RHC) share price pushes higher on US$1.35bn proposal for Asian JV

Ramsay has received an offer for its joint venture…

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Ramsay has responded to speculation and confirmed that it has received an offer for its Asian joint venture.
  • IHH Healthcare Berhad has tabled a US$1.35 billion offer for the joint venture.
  • Ramsay has granted IHH with due dilligence.

The Ramsay Health Care Limited (ASX: RHC) share price is pushing higher on Tuesday.

In afternoon trade, the private hospital operator's shares are up 2% to $64.60.

Despite this gain, the Ramsay share price is still down 10% since the start of the year.

Why is the Ramsay share price pushing higher?

Investors have bidding the Ramsay share price higher today after the healthcare giant responded to media speculation relating to its Asian operations.

According to the release, Ramsay and Sime Darby Holdings have received a confidential, conditional, non-binding, indicative proposal from IHH Healthcare Berhad to acquire 100% of their 50:50 joint venture in Asia, Ramsay Sime Darby Health Care Sdn.

The release notes that under the indicative proposal, the conditional indicative enterprise value for Ramsay Sime Darby is MYR5,670 million (or US$1.35 billion) on a cash free, debt free basis.

Though, the indicative proposal remains subject to conditions including the completion of satisfactory due diligence and the negotiation and finalisation of a sale and purchase agreement.

What now?

Ramsay and its joint venture partner appear to have seen value in the offer from IHH Healthcare Berhad.

The release reveals that after reviewing the proposal, both Ramsay and Sime Darby Holdings have agreed to a period of exclusivity for four weeks when due diligence commences to allow IHH Healthcare Berhad to conduct due diligence and negotiate a sale and purchase agreement.

Though, management warns that discussions between Ramsay, Sime Darby Holdings and IHH Healthcare Berhad are preliminary and no agreement has been reached in relation to the indicative proposal. As such, there is no guarantee that an agreement will be reached in respect of the proposal or that a transaction will eventuate.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Good news out of China has this drug company's shares higher

A major new market will open up following this approval.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

This rising ASX 200 stock isn't done yet – or is it?

Inching closer to FDA approval, the share price is falling. Analysts still see 21% to 106% upside.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »

Two boys lie in the grass arm wrestling.
Healthcare Shares

Is CSL or Sonic Healthcare the smarter ASX healthcare share buy?

This ASX heavyweight has potential to deliver superior returns but is more volatile.

Read more »